Possibilities of vildagliptin in optimal control of type 2 diabetes mellitus

• Main Author: V.I. Pankiv
• Format: Article
• Language: English
• Published: Publishing House Zaslavsky 2019-09-01
• Series: Mìžnarodnij Endokrinologìčnij Žurnal
• Subjects: type 2 diabetes mellitus; glucagon-like peptide-1; glucose-dependent insulinotropic polypeptide; insulin resistance; vildagliptin; efficiency; review
• Online Access: http://iej.zaslavsky.com.ua/article/view/185411

Incretin hormones are important for the normal functioning of pancreatic islet cells and glucose homeostasis. In type 2 diabetes mellitus, there is a violation of the sensiti­vity of pancreatic α- and β-cells, which leads to progressive insufficient insulin secretion, insulin resistance due to excessive production of glucagon during periods of postprandial hyperglycemia. In addition, type 2 diabetes mellitus is associated with an increase in lipotoxicity directly related to insulin resistance. The literature review provides data on the safety and efficacy of vildagliptin in patients with type 2 diabetes mellitus, as well as on the pancreatic effects of incretin-targeted therapy. It is clinically confirmed that vildagliptin effectively reduces the level of glycated hemoglobin, has a minimal risk of hypoglycemia and is able to maintain a normal body weight. In addition, vildagliptin inhibits postprandial triglyceride production and decreases fas­ting lipolysis, possibly affecting the inhibition of lipid absorption and triglyceride stores in non-adipose tissue cells.